[go: up one dir, main page]

DE60328138D1 - Zwischenprodukte für die Herstellung von Dioxan-2-alkylcarbamaten - Google Patents

Zwischenprodukte für die Herstellung von Dioxan-2-alkylcarbamaten

Info

Publication number
DE60328138D1
DE60328138D1 DE60328138T DE60328138T DE60328138D1 DE 60328138 D1 DE60328138 D1 DE 60328138D1 DE 60328138 T DE60328138 T DE 60328138T DE 60328138 T DE60328138 T DE 60328138T DE 60328138 D1 DE60328138 D1 DE 60328138D1
Authority
DE
Germany
Prior art keywords
alkylcarbamaten
intermediates
dioxane
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60328138T
Other languages
English (en)
Inventor
Ahmed Abouabdellah
Michele Bas
Gihad Dargazanli
Christian Hoornaert
Adrien Tak Li
Florence Medaisko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Application granted granted Critical
Publication of DE60328138D1 publication Critical patent/DE60328138D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • AIDS & HIV (AREA)
DE60328138T 2002-08-29 2003-08-27 Zwischenprodukte für die Herstellung von Dioxan-2-alkylcarbamaten Expired - Lifetime DE60328138D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0210707A FR2843964B1 (fr) 2002-08-29 2002-08-29 Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
DE60328138D1 true DE60328138D1 (de) 2009-08-06

Family

ID=31502974

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60328138T Expired - Lifetime DE60328138D1 (de) 2002-08-29 2003-08-27 Zwischenprodukte für die Herstellung von Dioxan-2-alkylcarbamaten
DE60323754T Expired - Lifetime DE60323754D1 (de) 2002-08-29 2003-08-27 Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60323754T Expired - Lifetime DE60323754D1 (de) 2002-08-29 2003-08-27 Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung

Country Status (34)

Country Link
US (4) US7119116B2 (de)
EP (2) EP1840125B1 (de)
JP (2) JP4585854B2 (de)
KR (2) KR101139160B1 (de)
CN (3) CN100491368C (de)
AR (1) AR041053A1 (de)
AT (2) ATE434598T1 (de)
AU (1) AU2003274292B2 (de)
BR (1) BR0313846A (de)
CA (2) CA2700319C (de)
CO (1) CO5700820A2 (de)
CY (2) CY1108792T1 (de)
DE (2) DE60328138D1 (de)
DK (2) DK1537096T3 (de)
EA (1) EA008218B1 (de)
ES (2) ES2312808T3 (de)
FR (1) FR2843964B1 (de)
HR (2) HRP20090270B1 (de)
IL (1) IL166882A (de)
IS (1) IS2733B (de)
MA (1) MA27390A1 (de)
ME (2) MEP24208A (de)
MX (1) MXPA05002319A (de)
NO (2) NO331165B1 (de)
NZ (1) NZ538404A (de)
PL (1) PL209339B1 (de)
PT (2) PT1840125E (de)
RS (2) RS20100169A (de)
SI (2) SI1537096T1 (de)
TN (1) TNSN05057A1 (de)
TW (2) TWI337606B (de)
UA (1) UA82847C2 (de)
WO (1) WO2004020430A2 (de)
ZA (1) ZA200501537B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
CA2501506C (en) * 2002-10-07 2014-02-11 Daniele Piomelli Modulation of anxiety through blockade of anandamide hydrolysis
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
FR2866885B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
FR2866886B1 (fr) 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) * 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
US7269708B2 (en) * 2004-04-20 2007-09-11 Rambus Inc. Memory controller for non-homogenous memory system
US20080103209A1 (en) * 2004-04-23 2008-05-01 The Regents Of The University Of California Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists
DE102004039326A1 (de) * 2004-08-12 2006-02-16 Abbott Gmbh & Co. Kg Neue medizinische Verwendungen und Verfahren
AU2006215080B2 (en) 2005-02-17 2011-03-10 Astellas Pharma Inc. Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
FR2885364B1 (fr) * 2005-05-03 2007-06-29 Sanofi Aventis Sa Derives d'alkyl-, alkenyl-et alkynylcarbamates, leur preparation et leur application en therapeutique
US20080045513A1 (en) * 2006-08-18 2008-02-21 N.V. Organon Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
WO2008030752A2 (en) * 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
US20090099240A1 (en) * 2006-10-02 2009-04-16 N.V. Organon Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity
US20080119549A1 (en) * 2006-11-20 2008-05-22 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
FR2941696B1 (fr) * 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
TW201044234A (en) * 2009-06-08 2010-12-16 Chunghwa Picture Tubes Ltd Method of scanning touch panel
CA2773590C (en) 2009-09-09 2017-09-05 Keiji Adachi 8-oxodihydropurine derivative
US8274566B2 (en) * 2009-10-09 2012-09-25 John Mezzalingua Associates, Inc. Modulation analyzer and level measurement device
EP2545914A1 (de) 2011-07-11 2013-01-16 Sanofi 2-Amino-2-oxoethyl-trrans-3-[5-(6-methoxy-naphtalen-yl)-1,3-dioxan-2-yl]propyl-carbamat zur Verwendung bei der Behandlung von anhaltendem Krebsschmerz
EP2545915A1 (de) 2011-07-11 2013-01-16 Sanofi 2-Amino-2-oxoethyl-trrans-3-[5-(6-methoxy-naphtalen-yl)-1,3-dioxan-2-yl]propyl-carbamat zur Verwendung bei der Behandlung von anhaltendem Krebsschmerz
JP2015508407A (ja) * 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
CN114835726B (zh) * 2022-03-24 2024-01-26 上海诺精生物科技有限公司 一类抑制肿瘤细胞干性的化合物及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2064057T3 (es) * 1990-06-15 1995-01-16 Synthelabo Unos derivados de 2-(aminoalquil)-5-(arilalquil)-1,3-dioxanos, su preparacion y su aplicacion en terapeutica.
US5173506A (en) * 1990-08-16 1992-12-22 Schering Corporation N-(mercaptoalkyl)ureas and carbamates
FR2742152B1 (fr) * 1995-12-06 1998-01-16 Synthelabo Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
AT403579B (de) * 1995-12-07 1998-03-25 Agrolinz Melamin Gmbh Verfahren zur herstellung von hochreinem melamin
JP2002502412A (ja) 1997-06-05 2002-01-22 サノフィ−サンテラボ ５−ナフタレン−１−イル−１，３−ジオキサン誘導体、製造方法および治療用途
SK15602000A3 (sk) * 1998-04-16 2001-03-12 Texas Biotechnology Corporation Zlúčeniny, ktoré inhibujú viazanie integrínov na ich receptory
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
HRP20050190B1 (hr) 2013-10-25
NO20051051L (no) 2005-03-29
DE60323754D1 (de) 2008-11-06
US20100280076A1 (en) 2010-11-04
RS51085B (sr) 2010-10-31
KR101139160B1 (ko) 2012-04-26
EP1537096B1 (de) 2008-09-24
JP4585854B2 (ja) 2010-11-24
PT1537096E (pt) 2008-12-11
EP1840125A2 (de) 2007-10-03
HK1108157A1 (zh) 2008-05-02
NO20110598L (no) 2005-03-29
AR041053A1 (es) 2005-04-27
TWI294878B (en) 2008-03-21
RS20050182A (sr) 2007-09-21
CO5700820A2 (es) 2006-11-30
IL166882A (en) 2010-12-30
RS20100169A (sr) 2011-04-30
CN1777595A (zh) 2006-05-24
US7119116B2 (en) 2006-10-10
MEP24208A (en) 2010-06-10
TW200422294A (en) 2004-11-01
ZA200501537B (en) 2006-10-25
NO335866B1 (no) 2015-03-09
SI1537096T1 (sl) 2009-02-28
NZ538404A (en) 2007-07-27
BR0313846A (pt) 2005-09-27
AU2003274292A1 (en) 2004-03-19
UA82847C2 (en) 2008-05-26
CA2496040A1 (en) 2004-03-11
TWI337606B (en) 2011-02-21
WO2004020430A2 (fr) 2004-03-11
CN101906071A (zh) 2010-12-08
DK1537096T3 (da) 2009-02-02
EP1840125B1 (de) 2009-06-24
ME00108B (me) 2010-10-10
CY1109441T1 (el) 2014-08-13
CN100491368C (zh) 2009-05-27
CY1108792T1 (el) 2014-04-09
IS2733B (is) 2011-04-15
MXPA05002319A (es) 2005-06-08
JP2010248218A (ja) 2010-11-04
EA200500268A1 (ru) 2005-10-27
FR2843964B1 (fr) 2004-10-01
CN101445504A (zh) 2009-06-03
PT1840125E (pt) 2009-09-29
EP1537096A2 (de) 2005-06-08
ATE434598T1 (de) 2009-07-15
DK1840125T3 (da) 2009-11-09
IS7699A (is) 2005-02-17
KR101051192B1 (ko) 2011-07-21
AU2003274292B2 (en) 2009-05-28
FR2843964A1 (fr) 2004-03-05
MA27390A1 (fr) 2005-06-01
ATE409184T1 (de) 2008-10-15
KR20100134807A (ko) 2010-12-23
ES2312808T3 (es) 2009-03-01
CA2496040C (en) 2011-04-05
WO2004020430A3 (fr) 2004-04-22
ES2329181T3 (es) 2009-11-23
NO331165B1 (no) 2011-10-24
JP2005539045A (ja) 2005-12-22
HRP20090270A2 (hr) 2009-09-30
CA2700319A1 (en) 2004-03-11
JP5244863B2 (ja) 2013-07-24
HRP20050190A2 (en) 2005-10-31
TW200738667A (en) 2007-10-16
US7777057B2 (en) 2010-08-17
SI1840125T1 (sl) 2009-12-31
CA2700319C (en) 2012-07-17
PL209339B1 (pl) 2011-08-31
US8119687B2 (en) 2012-02-21
US20090286868A1 (en) 2009-11-19
KR20050059108A (ko) 2005-06-17
EA008218B1 (ru) 2007-04-27
CN101445504B (zh) 2010-12-29
PL375753A1 (en) 2005-12-12
US20050182130A1 (en) 2005-08-18
EP1840125A3 (de) 2007-11-21
US20060247290A1 (en) 2006-11-02
TNSN05057A1 (fr) 2007-05-14
HRP20090270B1 (hr) 2015-12-04
HK1074445A1 (zh) 2005-11-11

Similar Documents

Publication Publication Date Title
DE60328138D1 (de) Zwischenprodukte für die Herstellung von Dioxan-2-alkylcarbamaten
DE602006010132D1 (de) Zwischenprodukte für die Herstellung von Trans-5-Chlor-2-Methyl-2,3,3a,12b-Tetrahydro-1h-DibenzÄ2,3:6,7ÜOxepinoÄ4,5-cÜPyrrol
DE69937077D1 (de) Zwischenprodukte für die Herstellung von Imidazo-Pyridin-Derivate
DE60216823D1 (de) Zwischenprodukten für die Herstellung von Pyridazinon Aldose Reductase Inhibitoren.
CR8226A (es) Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos
DE50300979D1 (de) Verwendung von Makromonomeren für die Herstellung von Acrylathaftklebemassen
EP1352072A4 (de) Formulierungen für die zuführung von nukleinsäuren
ITMI20022704A1 (it) Procedimento per la produzione di mesitilene e durene.
DE602004004777D1 (de) Kontinuierliches verfahren für die herstellung von polyamiden
ATE474824T1 (de) Herstellung von olefinen
DE602004013599D1 (de) Herstellung von somatostatinpeptiden
DE60238030D1 (de) Katalysatorzusammensetzung für die Herstellung von Polyolefinen
ITMI20030346A1 (it) Procedimento per la produzione di mesitilene.
ITMI20031994A1 (it) Procedimento per la preparazione di fludarabina fosfato
DE602005017357D1 (de) Überwachungseinrichtung für die herstellung von zusammensetzungen
DE60227652D1 (de) Verfahren für die herstellung von hydroxyethylaminen
ITMI20031670A1 (it) Processo per la preparazione di cilostazolo e di suoi intermedi.
DE60224968D1 (de) Prozess für die Herstellung von 5-Arylpentanolen
DE602004009917D1 (de) Zwischenprodukt für die herstellung von pioglitazon
FR2843451B1 (fr) Fronde du type lance-pierres
DE60331445D1 (de) Polypropylenfasern für die herstellung von thermisch verfestigten vliesstoffen
ITMI20030352A1 (it) Metodo per la sintesi di metiltriossorenio.
ITTO20020997A1 (it) Procedimento autoalllineato per la fabbricazione di
AP2006003603A0 (en) Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof.
DE50308029D1 (de) Kontrastmittel für die lymphknoten-darstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition